Co-founded by Harvard faculty, Garuda has launched with $72m in series A financing to advance blood stem cell therapies.
Garuda Therapeutics, a US-based developer of therapeutics based on blood stem cells advancing Harvard University research, launched yesterday with $72m in series A funding co-led by Aisling Capital, Northpond Ventures and Orbimed.
Healthcare provider Mass General Brigham took part in the round through strategic investment vehicle Mass General Brigham Ventures, while Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management and National Resilience also invested.
Garuda is working on technology intended to generate blood stem cells without…